Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Future Oncology (London, England)|June 13, 2022
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breastElisa Agostinetto, Guilherme Nader-Marta, Marianne Paesmans, et al.
Cancer|October 19, 2018
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trialsMatteo Lambertini, Samuel Martel, Christine Campbell, et al.
Journal of the National Cancer Institute|May 23, 2018
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA SubstudyMichail Ignatiadis, Gert Van den Eynden, Salgado Roberto, et al.
BMC Medicine|August 4, 2015
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancerAmir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
NPJ Breast Cancer|December 19, 2020
Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patientsAli Bohlok, Peter Vermeulen, Sophia Leduc, et al.
Cytometry. Part B, Clinical Cytometry|February 22, 2011
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility studyJaco Kraan, Stefan Sleijfer, Michiel H Strijbos, et al.
JAMA Oncology|December 4, 2015
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer RecurrenceMichail Ignatiadis, Hatem A Azim, Christine Desmedt, et al.
Journal for Immunotherapy of Cancer|December 6, 2023
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trialAlex De Caluwe, Emanuela Romano, Philip Poortmans, et al.
Plos One|July 26, 2016
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast CancerMichail Ignatiadis, Dimitrios Zardavas, Marc Lemort, et al.
Genes, Chromosomes & Cancer|August 21, 2010
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumorsDavid J McBride, Arto K Orpana, Christos Sotiriou, et al.
Pageof 10